NO20062303L - Pyrazinderivater og farmasoytisk anvendelse derav - Google Patents
Pyrazinderivater og farmasoytisk anvendelse deravInfo
- Publication number
- NO20062303L NO20062303L NO20062303A NO20062303A NO20062303L NO 20062303 L NO20062303 L NO 20062303L NO 20062303 A NO20062303 A NO 20062303A NO 20062303 A NO20062303 A NO 20062303A NO 20062303 L NO20062303 L NO 20062303L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- dementia
- pharmaceutical use
- pyrazine derivatives
- parkinson
- Prior art date
Links
- 150000003216 pyrazines Chemical class 0.000 title abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000013677 cerebrovascular dementia Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 abstract 1
- -1 pyrazine compound Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003905895A AU2003905895A0 (en) | 2003-10-27 | Pyrazine Derivative and Pharmaceutical use Thereof | |
| AU2004902764A AU2004902764A0 (en) | 2004-05-24 | Pyrazine Derivative and Pharmaceutical Use Thereof | |
| PCT/JP2004/016193 WO2005040151A1 (en) | 2003-10-27 | 2004-10-25 | Pyrazine derivatives and pharmaceutical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20062303L true NO20062303L (no) | 2006-07-19 |
Family
ID=34523512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20062303A NO20062303L (no) | 2003-10-27 | 2006-05-22 | Pyrazinderivater og farmasoytisk anvendelse derav |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7407961B2 (pt) |
| EP (1) | EP1678160A1 (pt) |
| JP (1) | JP4650419B2 (pt) |
| KR (1) | KR20060123208A (pt) |
| AR (1) | AR046200A1 (pt) |
| BR (1) | BRPI0415863A (pt) |
| CA (1) | CA2543644A1 (pt) |
| NO (1) | NO20062303L (pt) |
| RU (1) | RU2006118325A (pt) |
| TW (1) | TW200526620A (pt) |
| WO (1) | WO2005040151A1 (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1742935B1 (en) | 2004-04-13 | 2010-02-24 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| CA2590261C (en) * | 2004-12-27 | 2011-08-16 | Alcon, Inc. | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions |
| EP2336117A1 (en) | 2005-05-26 | 2011-06-22 | Neuron Systems, Inc | Heterocyclic compounds for treating retinal diseases |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| NL2000284C2 (nl) * | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
| CA2655857C (en) * | 2006-06-22 | 2014-12-02 | Mallinckrodt Inc. | Pyrazine derivatives with extended conjugation and uses thereof |
| FR2945609B1 (fr) * | 2009-05-12 | 2013-03-29 | Avancis Gmbh & Co Kg | Dispositif de fixation et procede de montage de modules solaires. |
| AU2010313392B2 (en) * | 2009-10-30 | 2015-07-09 | Janssen Pharmaceutica Nv | Pyrazines as delta opioid receptor modulators |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| DK2531492T3 (en) | 2010-02-05 | 2016-07-04 | Heptares Therapeutics Ltd | 1,2,4-triazin-4-amine derivatives |
| CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| JP6779204B2 (ja) * | 2014-11-18 | 2020-11-04 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ａ２ａ拮抗薬特性を有するアミノピラジン化合物 |
| CN108135907A (zh) | 2015-08-21 | 2018-06-08 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| US11129823B2 (en) | 2016-05-09 | 2021-09-28 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| PH12019500056B1 (en) * | 2016-07-12 | 2024-01-31 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| BR112019015075A2 (pt) | 2017-01-23 | 2020-03-10 | Revolution Medicines, Inc. | Compostos bicíclicos como inibidores de shp2 alostéricos |
| SG11201906412SA (en) | 2017-01-23 | 2019-08-27 | Revolution Medicines Inc | Pyridine compounds as allosteric shp2 inhibitors |
| US10414732B2 (en) | 2017-03-16 | 2019-09-17 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| BR112020000962A2 (pt) | 2017-07-18 | 2020-07-14 | Nuvation Bio Inc. | compostos de 1,8-naftiridinona e usos dos mesmos |
| JP2020527588A (ja) * | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| JP7356414B2 (ja) | 2017-09-07 | 2023-10-04 | レヴォリューション・メディスンズ，インコーポレイテッド | がんを治療するためのｓｈｐ２阻害剤組成物および方法 |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| SG11202002941WA (en) | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| CA3084058A1 (en) | 2017-12-15 | 2019-06-20 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
| CN118978535A (zh) | 2018-05-01 | 2024-11-19 | 锐新医药公司 | 作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物 |
| EP3833660A4 (en) | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND THEIR USES |
| JP7540996B2 (ja) * | 2018-08-17 | 2024-08-27 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | ピラジン化合物およびその使用 |
| CN111377906B (zh) * | 2018-12-28 | 2022-09-02 | 四川科伦博泰生物医药股份有限公司 | 取代的吡嗪化合物及其制备方法和用途 |
| EP3911325A4 (en) * | 2019-01-18 | 2022-10-12 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| CN113939291A (zh) | 2019-01-18 | 2022-01-14 | 诺维逊生物股份有限公司 | 1,8-萘啶酮化合物及其用途 |
| BR112021013936A2 (pt) | 2019-01-18 | 2021-09-21 | Nuvation Bio Inc. | Compostos heterocíclicos como antagonistas de adenosina |
| CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2021146629A1 (en) * | 2020-01-17 | 2021-07-22 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| WO2021146631A1 (en) * | 2020-01-17 | 2021-07-22 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072746A (en) * | 1975-10-14 | 1978-02-07 | Sterling Drug Inc. | 3-Amino-5-(pyridinyl)-2(1H)-pyridinones |
| US4313951A (en) * | 1979-11-26 | 1982-02-02 | Sterling Drug Inc. | 3-Substituted-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones, their cardiotonic use and intermediates therefor |
| CA2209465C (en) * | 1996-07-11 | 2008-04-29 | Lonza Ag | Process for preparing 3-alkoxy-5-alkylpyrazin-2-amines |
| US6548503B1 (en) * | 1998-11-04 | 2003-04-15 | Smithkline Beecham Corporation | Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| CN1231473C (zh) * | 2000-02-16 | 2005-12-14 | 神经能质公司 | 取代的芳基吡嗪 |
| ATE293962T1 (de) * | 2000-02-25 | 2005-05-15 | Hoffmann La Roche | Adenosin-rezeptor modulatoren |
| AU2001277741B2 (en) * | 2000-08-11 | 2005-12-22 | Eisai R&D Management Co., Ltd. | 2-aminopyridine compounds and use thereof as drugs |
| US6673802B2 (en) * | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| TWI330183B (pt) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| WO2003045924A1 (en) * | 2001-11-21 | 2003-06-05 | Pharmacia & Upjohn Company | Substituted aryl 1,4-pyrazine derivatives |
| AU2002950853A0 (en) * | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
| EP1554258A1 (en) * | 2002-08-20 | 2005-07-20 | Neurogen Corporation | 5-substituted-2-arylpyrazines as modulators of crf receptors |
-
2004
- 2004-10-25 WO PCT/JP2004/016193 patent/WO2005040151A1/en not_active Ceased
- 2004-10-25 CA CA002543644A patent/CA2543644A1/en not_active Abandoned
- 2004-10-25 BR BRPI0415863-6A patent/BRPI0415863A/pt not_active Application Discontinuation
- 2004-10-25 RU RU2006118325/04A patent/RU2006118325A/ru not_active Application Discontinuation
- 2004-10-25 JP JP2006519017A patent/JP4650419B2/ja not_active Expired - Fee Related
- 2004-10-25 KR KR1020067010364A patent/KR20060123208A/ko not_active Withdrawn
- 2004-10-25 EP EP04793294A patent/EP1678160A1/en not_active Withdrawn
- 2004-10-26 TW TW093132552A patent/TW200526620A/zh unknown
- 2004-10-26 US US10/972,340 patent/US7407961B2/en not_active Expired - Fee Related
- 2004-10-26 AR ARP040103894A patent/AR046200A1/es unknown
-
2006
- 2006-05-22 NO NO20062303A patent/NO20062303L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060123208A (ko) | 2006-12-01 |
| JP4650419B2 (ja) | 2011-03-16 |
| US20050113387A1 (en) | 2005-05-26 |
| TW200526620A (en) | 2005-08-16 |
| AR046200A1 (es) | 2005-11-30 |
| CA2543644A1 (en) | 2005-05-06 |
| WO2005040151A1 (en) | 2005-05-06 |
| EP1678160A1 (en) | 2006-07-12 |
| US7407961B2 (en) | 2008-08-05 |
| JP2007510620A (ja) | 2007-04-26 |
| BRPI0415863A (pt) | 2007-01-09 |
| RU2006118325A (ru) | 2007-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0415863A (pt) | derivados pirazina e seus usos farmacêuticos | |
| CY1119971T1 (el) | Αναστολεις gsk-3 | |
| WO2005095384A8 (en) | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists | |
| BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
| NO20054082L (no) | Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| EA200401114A3 (ru) | Замещённые гидроксиэтиламины | |
| CY1108276T1 (el) | Ενωσεις που επηρεαζουν τη γλυκοκιναση | |
| CY1105341T1 (el) | Συνθεσεις για τη θepαπεια της νοσου του παρκινσον, οι οποιες πepιεχουν εναν ανταγωνιστη του υποδοχεα cb1 και ενα χημικο προϊον που διεγειρει τους νευροδιαβιβαστες του ντοπαμινepγικου συστηματος στον εγκεφαλο | |
| CY1105621T1 (el) | Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους | |
| CY1108514T1 (el) | Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων | |
| CY1110745T1 (el) | Παραγωγα πυρρολιδονης ως αναστολεις μαοβ | |
| DE60226729D1 (de) | Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| BRPI0416212A (pt) | derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação | |
| DE602004028150D1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| NO20062020L (no) | 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika | |
| DK2527315T3 (da) | Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom | |
| ATE253918T1 (de) | Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| NO20060020L (no) | 3-fluorpiperidiner som NMDA/NR2B-antagonister | |
| WO2004022540A3 (en) | Pyridazinone and pyridone derivatives as adenosine antagonists | |
| TW200736255A (en) | 5-(Substituted)-pyrazolopiperidines | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |